



May 25, 2007

Dear HIV Provider,

In our continuing commitment to innovate healthcare for patients, laboratories, and physicians; Roche Diagnostics is pleased to offer you and your patients our next evolution in HIV viral load testing, the COBAS[®] AmpliPrep[®] / COBAS[®] TaqMan[®] HIV-1 test.

What this means to you is consolidation of our previous HIV-1 MONITOR Standard and UltraSensitive formats into one FDA-approved assay. Regardless of how long ago your patient was diagnosed or the duration of treatment, the new dynamic range of this test delivers standard of care sensitivity (50 copies/mL) and quantitation between 48 copies and 10, 000,000 copies. Additionally, there is no need to re-baseline or recalibrate your patients because we have demonstrated a high correlation between the new COBAS[®] AmpliPrep[®] / COBAS[®] TaqMan[®] HIV-1 test and other HIV viral load methodologies.

At Roche we built upon our 11 years of clinical HIV diagnostic experience to ensure this viral load test continues to deliver full Group M subtype coverage, including the rare non-B subtypes. Additionally, it is important to note that Roche PCR was the key measure upon which all HIV combination therapies received FDA approval.

In partnership with your local laboratory, Roche Diagnostics Medical and Scientific Affairs group (indianapolis.mdxmsa@roche.com) is here to support you. We appreciate your continued use and application of laboratory tests to personalize HIV care and treatment for all of your patients.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Michael Samoszuk".

Michael Samoszuk, M.D., Chief Medical Officer
Roche Diagnostics Corporation

A handwritten signature in black ink, appearing to read "Tadd Lazarus".

Tadd Lazarus, M.D., Medical Director
Roche Diagnostics Corporation